Clinical pharmacokinetics of imatinib.

@article{Peng2005ClinicalPO,
  title={Clinical pharmacokinetics of imatinib.},
  author={Bin Peng and Peter Lloyd and Horst F Schran},
  journal={Clinical pharmacokinetics},
  year={2005},
  volume={44 9},
  pages={879-94}
}
Imatinib is a potent and selective inhibitor of the protein tyrosine kinase Bcr-Abl, platelet-derived growth factor receptors (PDGFRalpha and PDGFRbeta) and KIT. Imatinib is approved for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST), which have dysregulated activity of an imatinib-sensitive kinase as the underlying pathogenetic feature. Pharmacokinetic studies of imatinib in healthy volunteers and patients with CML, GIST and other cancers show that… CONTINUE READING
Highly Influential
This paper has highly influenced 21 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 166 extracted citations

Similar Papers

Loading similar papers…